AUPH - The Buzz Show: Aurinia Pharmaceuticals (NASDAQ: AUPH) Receives FDA Approval for LUPKYNIS

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Aurinia Pharmaceuticals Receives FDA Approval for LUPKYNIS”

Aurinia Pharmaceuticals (NASDAQ: AUPH) soared over 37% in premarket trading after the FDA approved its oral therapy for lupus nephritis.

The U.S. Food and Drug Administration recently approved LUPKYNISTM in combination with a background immunosuppressive therapy regimen, making it the first FDA-approved oral therapy to treat adult patients with active lupus nephritis.

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

For more information, please visit: Aurinia Pharmaceuticals Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Aurinia Pharmaceuticals (NASDAQ: AUPH) Receives FDA Approval for LUPKYNIS first appeared on Financial Buzz .

For further details see: